Can analysts adopt a bullish outlook for ICON Public Limited Company (NASDAQ:ICLR)?

April 20, 2018 - By Marguerite Chambers

ICON Public Limited Company (NASDAQ:ICLR) Logo

ICON Public Limited Company (NASDAQ:ICLR) Ratings Coverage

Among 8 analysts covering Icon plc (NASDAQ:ICLR), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Icon plc had 15 analyst reports since October 26, 2017 according to SRatingsIntel. Barclays Capital maintained ICON Public Limited Company (NASDAQ:ICLR) rating on Friday, October 27. Barclays Capital has “Equal-Weight” rating and $120 target. The rating was maintained by Jefferies with “Buy” on Thursday, February 15. The firm has “Buy” rating by SunTrust given on Monday, October 30. Robert W. Baird maintained ICON Public Limited Company (NASDAQ:ICLR) rating on Thursday, October 26. Robert W. Baird has “Buy” rating and $134.0 target. The stock of ICON Public Limited Company (NASDAQ:ICLR) earned “Buy” rating by KeyBanc Capital Markets on Wednesday, January 10. As per Thursday, February 15, the company rating was maintained by Mizuho. SunTrust maintained ICON Public Limited Company (NASDAQ:ICLR) on Monday, January 22 with “Buy” rating. On Monday, November 13 the stock rating was maintained by KeyBanc Capital Markets with “Buy”. The firm has “Buy” rating given on Thursday, February 15 by Credit Suisse. The firm has “Hold” rating by Mizuho given on Thursday, October 26. Below is a list of ICON Public Limited Company (NASDAQ:ICLR) latest ratings and price target changes.

03/04/2018 Broker: Evercore Old Rating: Outperform New Rating: In-Line Old Target: $126 Downgrade
15/02/2018 Broker: Robert W. Baird Rating: Buy New Target: $136.0 Maintain
15/02/2018 Broker: Jefferies Rating: Buy New Target: $141.0 Maintain
15/02/2018 Broker: Credit Suisse Rating: Buy New Target: $131.0 Upgrade
15/02/2018 Broker: Mizuho Rating: Hold New Target: $114.0 Maintain
24/01/2018 Broker: Mizuho Rating: Hold New Target: $109.0 Maintain
22/01/2018 Broker: SunTrust Rating: Buy New Target: $133.0 Maintain
19/01/2018 Broker: Evercore Rating: Outperform New Target: $126 Initiates Coverage On
10/01/2018 Broker: KeyBanc Capital Markets Rating: Buy New Target: $130.0 Maintain
09/01/2018 Broker: Jefferies Rating: Buy New Target: $145.0 Maintain

The stock decreased 1.21% or $1.44 during the last trading session, reaching $117.64. About 277,436 shares traded. ICON Public Limited Company (NASDAQ:ICLR) has risen 52.69% since April 20, 2017 and is uptrending. It has outperformed by 41.14% the S&P500.

ICON Public Limited Company, a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. The company has market cap of $6.36 billion. The firm specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It has a 22.93 P/E ratio. The Company’s clinical development services comprise product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, clinical research center, investigator site, patient recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety and risk monitoring, clinical data management, strategic analysis and data operation, regulatory consulting, and medical reporting and pharmacovigilance services.

ICON Public Limited Company (NASDAQ:ICLR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.